REFERENCES
4. Ahmad A, Maitah MY, Ginnebaugh KR, Li Y, Bao B, et al. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol 2013;6:77.
5. Lu Y, Liu Y, Oeck S, Glazer PM. Hypoxia promotes resistance to EGFR inhibition in NSCLC Cells via the histone demethylases, LSD1 and PLU-1. Mol Cancer Res 2018;16:1458-69.
6. Yue J, Lv D, Wang C, Li L, Zhao Q, et al. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3. Oncogene 2018;37:4300-12.
7. White JC, Pucci P, Crea F. The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors. Cancer Drug Resist 2019;2:326-34.
8. Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics 2019;11:7.
9. Schwarzenbach H, Gahan PB. Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients. Cancer Drug Resist 2019;2:271-96.
10. Ahmad A. Epigenetics in personalized management of lung cancer. Adv Exp Med Biol 2016;890:111-22.
11. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med 2020;12:8.
12. Goutsouliak K, Veeraraghavan J, Sethunath V, Angelis CD, Osborne CK, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol 2019. Epub ahead of print. doi: 10.1038/s41571-019-0299-9
13. Ponnusamy L, Mahalingaiah PKS, Chang YW, Singh KP. Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer. Cancer Drug Resist 2019;2:297-312.
14. Seno A, Mizutani A, Aizawa K, Onoue R, Masuda J, et al. Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation. Cancer Drug Resist 2019;2:335-50.
15. Janczar S, Janczar K, Pastorczak A, Harb H, Paige AJW, et al. The role of histone protein modifications and mutations in histone modifiers in pediatric B-cell progenitor acute lymphoblastic leukemia. Cancers (Basel) 2017;9.
16. Meyer LK, Hermiston ML. The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities. Cancer Drug Resist 2019;2:313-25.
17. Jia ZH, Wang XG, Zhang H. Overcome cancer drug resistance by targeting epigenetic modifications of centrosome. Cancer Drug Resist 2019;2:210-24.
18. Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity 2020;52:55-81.
19. Peixoto P, Renaude E, Boyer-Guittaut M, Hervouet E. Epigenetics, a key player of immunotherapy resistance. Cancer Drug Resist 2018;1:219-29.
20. Morales S, Monzo M, Navarro A. Epigenetic regulation mechanisms of microRNA expression. Biomol Concepts 2017;8:203-12.
21. Ahmad A, Li Y, Bao B, Kong D, Sarkar FH. Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals. Mol Nutr Food Res 2014;58:79-86.
22. Ediriweera MK, Cho SK. Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer. Pharmacol Ther 2019;206:107437.
